HEMATOLOGY

Eribulin mesylate (Halaven) has been granted an FDA priority review designation as a treatment for patients with advanced soft tissue sarcoma following chemotherapy.

Relapsed and Refractory CLL with Javier Pinilla-lbarz, MD, PhD and Paul Barr, MD

Relapsed and Refractory CLL with Javier Pinilla-lbarz, MD, PhD and Paul Barr, MD

Failure-free survival (FFS) for patients with follicular lymphoma has had a lack of improvement, fueling interest in new treatment strategies that may offer promise for better outcomes.

Single-agent ibrutinib (Imbruvica) data showed durable responses in patients with untreated or relapsed/refractory chronic lymphocytic leukemia (CLL).

New combination strategies are required for heterogeneity of mantle cell lymphoma (MCL), in order to improve outcomes.